Wipfli Financial Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Wipfli Financial Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1K	Buy	+87	New	+$879	﹤0.01%	2410

Other funds holding EWTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wipfli Financial Advisors's EWTX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Edgewise Therapeutics (EWTX) in Q3 2022: 87 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2410 among its holdings.

94 funds tracked by Wall St. Rank hold EWTX as of Q3 2022.

Wipfli Financial Advisors held 87 shares of Edgewise Therapeutics worth $1K as of Q3 2022.
Edgewise Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
Edgewise Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2410 holding.
94 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.